Mechanism of endothelial dysfunction in chronic kidney disease

Clinica Chimica Acta

Volumn 411, Issue 19-20, 2010, Pages 1412-1420

  Malyszko, Jolanta ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Adipocytokines; Chronic kidney disease; Diabetic nephropathy; Endothelium; Hemodialysis; Nitric oxide

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CD146 ANTIGEN; CD40 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; N(G),N(G) DIMETHYLARGININE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC OXIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PADGEM PROTEIN; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; ERYTHROPOIESIS; HEMODIALYSIS; HUMAN; HYPERLEPTINEMIA; HYPERTENSION; INSULIN RESISTANCE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SHEAR STRESS; THROMBOSIS; UREMIA; VASOCONSTRICTION;

ADIPOKINES; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; RENAL INSUFFICIENCY, CHRONIC;

EID: 77955052030     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.06.019     Document Type: Review

References (164)

1. Inagami T., Naruse M., Hoover R. Endothelium as an endocrine organ. Annu Rev Physiol 1995, 57:171-189.
2. Wolinsky H. A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherogenesis. Circ Res 1980, 47:301.
3. Simionescu M., Gafencu A., Antohe F. Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey. Microsc Res Tech 2002, 57:269-288.
4. Gross P.L., Aird W.C. The endothelium and thrombosis. Semin Thromb Hemost 2000, 26:463-478.
5. Wagner D.D., Frenette P.S. The vessel wall and its interactions. Blood 2008, 111:5271.
6. Stevens T., Rosenberg R., Aird W., et al. NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. Am J Physiol Cell Physiol 2001, 281:C1422-C1433.
7. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
8. Schiffrin E.L. A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol 2001, 38(suppl.2):S3-S6.
9. Verma S., Anderson T.J. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002, 105:546-549.
10. Endeman D.H., Schiffrin E.L. Endothelial dysfunction. J Am Soc Nephrol 2004, 15:1983-1992.
11. Panza J.A., Quyyumi A.A., Brush J.E., Epstein S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990, 323:22-27.
12. Bombeli T., Mueller M., Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997, 77:408-423.
13. Florey L. The endothelial cell. Br Med J 1966, 5512:487-490.
14. Ross R., Glomset J.A. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973, 180:1332-1339.
15. Schwartz S.M., Gajdusek C.M., Reidy M.A., Selden S.C., Haudenschild C.C. Maintenance of integrity in aortic endothelium. Fed Proc 1980, 39:2618-2625.
16. Endothelial dysfunction and the pathogenesis of atherosclerosis 1980, Springer-Verlag, New York. M.A. Gimbrone (Ed.).
17. Ludmer P.L., Selwyn A.P., Shook T.L., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986, 315:1046-1051.
18. Cybulsky M.I., Gimbrone M.A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 251:788-791.
19. Osborn L., Hession C., Tizard R., et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989, 59:1203-1211.
20. Hasstedt S.J., Bezemer I.D., Callas P.W., et al. Cell adhesion molecule 1: a novel risk factor for venous thrombosis. Blood 2009, 114:3084-3091.
21. Haber E. Scientific American molecular cardiovascular medicine 1995, Scientific American Medicine, New York.
22. Fens M.H., Mastrobattista E., de Graaff A.M., et al. Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells. Blood 2008, 111:4542-4550.
23. Andre P. P-selectin in haemostasis. Br J Haematol 2004, 126:298-306.
24. Barleon B., Reusch P., Totzke F., et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 2001, 4:143-154.
25. Hornig C., Barleon B., Ahmad S., Vuorela P., Ahmed A., Weich H.A. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 2000, 80:443-454.
26. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111:649-658.
27. Bombeli T., Schwartz B.R., Harlan J.M. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood 1999, 93:3831-3838.
28. Blann A.D., Woywodt A., Bertolini F., et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005, 93:228-235.
29. Chirinos J.A., Heresi G.A., Velasquez H., et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol 2005, 45:1467-1471.
30. Yoder M.C., Mead L.E., Prater D., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109:1801-1809.
31. Lynch S.F., Ludlam C.A. Plasma microparticles and vascular disorders. Br J Haematol 2007, 137:36-48.
32. Deregibus M.C., Cantaluppi V., Calogero R., et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007, 110:2440-2448.
33. Ghosh A., Li W., Febbraio M., et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest 2008, 118:1934-1943.
34. Shantsila E., Blann A.D., Lip G.Y. Circulating endothelial cells: from bench to clinical practice. J Thromb Haemost 2008, 6:865-868.
35. Mancuso P., Antoniotti P., Quarna J., et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 2009, 15:267-273.
36. Lindner A., Charra B., Sherrad D.J., Scribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974, 290:697-701.
37. Mallamaci F., Tripepi G., Cutrupi S., Malatino L.S., Zoccali C. Prognostic value ofcombined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005, 67:2330-2337.
38. Panichi V., Migliori M., De Pietro S., et al. C reactive protein in patients with chronic renal diseases. Ren Fail 2001, 23:551-562.
39. Stenvinkel P., Heimburger O., Wang T., Lindholm B., Bergstrom J., Elinder C.G. High serum hyaluronan indicates poor survival in renal replacement therapy. Am J Kidney Dis 1999, 34:1083-1088.
40. Chung S.H., Heimburger O., Stenvinkel P., Bergstrom J., Lindholm B. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 2001, 16:2240-2245.
41. Pecoits-Filho R., Heimburger O., Barany P., Suliman M. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003, 41:1212-1218.
42. Kuriyama S., Tomonari H., Yoshida H., Hikita M., Sakai O. Endothelial cell dysfunction in patients with impaired renal function. Nippon Jinzo Gakkai Shi 1996, 38:372-378.
43. Jacobson S.H., Egberg N., Hylander B., Lundahl J. Correlation between soluble markers of endothelial dysfunction in patients with renal failure. Am J Nephrol 2002, 22:42-47.
44. Bolton C.H., Downs L.G., Victory J.G., et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and proinflammatory cytokines. Nephrol Dial Transplant 2001, 16:1189-1197.
45. Małyszko J., Małyszko J.S., Mysliwiec M. Comparison of hemostasis between CAPD and HD patients. Perit Dial Int 2001, 21:158-165.
46. Małyszko J., Małyszko J.S., Myśliwiec M. Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis (CAPD). Kidney Blood Press Res 2004, 27:71-77.
47. Malyszko J., Malyszko J.S., Kozminski P., Pawlak K., Mysliwiec M. Adipokines, linking adipocytes and vascular function in hemodialyzed patients, may also be possibly related to CD146, a novel adhesion molecule. Clin Appl. Thromb Hemostas. 2008, 14:338-345.
48. Malyszko J., Malyszko J.S., Wolczynski S., Brzosko S., Mysliwiec M. Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab 2004, 89:4620-4627.
49. Gearing A.J.H., Hemingway I., Piggott R., Hughes J., Rees A.J., Cashman S.J. Soluble forms of vascular adhesion molecules. E-selectin, ICAM-1 and VCAM-1: Pathological significance. Ann NY Acad Sci 1992, 667:324-331.
50. Halliwell B. The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 1993, 23(suppl1):S118-S126.
51. Costa-Hong V., Bortolotto L.A., Jorgetti V., Consolim-Colombo F., Krieger E.M., Lima J.J. Oxidative stress and endothelial dysfunction in chronic kidney disease. Arq Bras Cardiol 2009, 92:381-386.
52. Ferretti G., Bacchetti T., Masciangelo S., Pallotta G. Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 2008, 41:381-386.
53. Dounousi E., Papavasiliou E., Makedou A., et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006, 48:752-760.
54. Zoccali C., Bode-Böger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117.
55. Nanayakkara P.W., Teerlink T., Stehouwer C.D., et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 2005, 68:2230-2236.
56. Ravani P., Tripepi G., Malberti F., Testa S., Mallamaci F., Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16:2449-2455.
57. Comper W.D., Hilliard L.M., Nikolic-Paterson D.J., et al. Disease-dependent mechanisms of albuminuria. Am J Physiol Ren Physiol 2008, 295:1589-1600.
58. Stehouwer C.D., Henry R.M., Dekker J.M., Nijpels G., Heine R.J., Bouter L.M. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction-the Hoorn Stud. Kidney Int 2004, 92(Suppl):S42-S44.
59. Klausen K., Borch-Johnsen K., Feldt-Rasmussen B., et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004, 110:32-35.
60. Stenvinkel P., Carrero J.J., Axelsson J., Lindholm B., Heimburger O., Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol 2008, 3:505-521.
61. Bakris G.L., Sarafidis P.A., Weir M.R., et al. ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375:1173-1181.
62. Aucella F., Maas R., Vigilante M., et al. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. Atherosclerosis 2009, 207:541-545.
63. Gris J.C., Branger B., Vecina F., Sabadani B., Fourcade J., Schved J.F. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994, 46:807-813.
64. Bonomini M., Reale M., Santarelli P., Stuard S., Settefrati N., Albertazzi A. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron 1998, 79:399-407.
65. Yilmaz M.I., Saglam M., Caglar K., et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006, 47:42-50.
66. Bahlmann F.H., De Groot K., Spandau J.M., et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004, 103:921-926.
67. Bahlmann F.H., DeGroot K., Duckert T., et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003, 64:1648-1652.
68. de Groot K., Bahlmann F.H., Bahlmann E., Menne J., Haller H., Fliser D. Kidney graft function determines endothelial progenitor cell number in renal transplant recipients. Transplantation 2005, 79:941-945.
69. Imanishi T., Kobayashi K., Kuki S., Takahashi C., Akasaka T. Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis 2006, 189:288-296.
70. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
71. Jie K.E., Zaikova M.A., Bergevoet M.W., et al. Progenitor cells and vascular function are impaired in patients with chronic kidney disease. Nephrol Dial Transplant 2010, 25:1875-1882.
72. Bahlmann F.H., de Groot K., Mueller O., Hertel B., Haller H., Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005, 45:526-529.
73. de Groot K., Bahlmann F.H., Sowa J., et al. Uremia causes endothelial progenitor cell deficiency. Kidney Int 2004, 66:641-646.
74. Loomans C.J., de Koning E.J., Staal F.J., et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004, 53:195-199.
75. Koç M., Bihorac A., Segal M.S. Circulating endothelial cells as potential markers of the state of the endothelium in hemodialysis patients. Am J Kidney Dis 2003, 42:704-712.
76. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003, 348:593-600.
77. Mohandas R., Segal M.S. Endothelial progenitor cells and endothelial vesicles - what is the significance for patients with chronic kidney disease?. Blood Purif 2010, 29:158-162.
78. Koc M., Richards H.B., Bihorac A., Ross E.A., Schold J.D., Segal M.S. Circulating endothelial cells are associated with future vascular events in hemodialysis patients. Kidney Int 2005, 67:1078-1083.
79. Rodríguez-Ayala E., Yao Q., Holmén C., Lindholm B., Sumitran-Holgersson S., Stenvinkel P. Imbalance between detached circulating endothelial cells and endothelial progenitor cells in chronic kidney disease. Blood Purif 2006, 24:196-202.
80. Di Marco G.S., Reuter S., Hillebrand U., et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 2009, 20:2235-2245.
81. Perticone F., Sciacqua A., Maio R., et al. Asymmetric dimethylarginine, l-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005, 46:518-523.
82. Raff U., Schwarz T.K., Schmidt B.M., Schneider M.P., Schmieder R.E. Renal resistive index-a valid tool to assess renal endothelial function in humans?. Nephrol Dial Transplant 2010, 25:1869-1874.
83. Faber D.R., de Groot P.G., Visseren F.L. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 2009, 10:554-563.
84. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apMI (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
85. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
86. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a c-AMP-dependent pathway. Circulation 2000, 102:1296-1301.
87. Ekmekci H., Ekmekc OB. The role of adiponectin in atherosclerosis and thrombosis. Clin Appl Thromb Hemost 2006, 12:163-168.
88. Yokota T., Oritani K., Takahashi I., et al. Adiponectin, a new meber of the family of soluble defence collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723-1732.
89. Okamoto Y., Arita Y., Nishida M., et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000, 32:47-50.
90. Karaduman M., Sengul A., Oktenli C., et al. Tissue levels of adiponectin, tumour necrosis factor-alpha, soluble intercellar adhesion molecule-1 and heart-type fatty acid-binding protein in human coronary atherosclerotic plaques. Clin Endocrinol 2006, 64:196-202.
91. Davies M.J., Gordon J.L., Gearing A.J., et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993, 171:223-229.
92. Yilmaz M.I., Saglam M., Qureshi A.R., et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008, 23:1621-1627.
93. Arita Y., Kihara S., Okamoto Y., et al. Paradoxical decrease of an adipocyte-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
94. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
95. Ouchi N., Ohishi M., Kihara S., et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42:231-234.
96. Shimabukuro M., Higa N., Asahi T., et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003, 88:3236-3240.
97. Tan K.C., Xu A., Chow W.S., et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004, 89:765-769.
98. Fernandez-Real JM, Castro A, Vazquez G, et al. Adiponectin is associated with vascular function independent of insulin sensitivity 2004;27: 739-745.
99. Koshimura J., Fujita H., Narita T., et al. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun 2004, 316:165-169.
100. Kawanami D., Maemura K., Takeda N., et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004, 314:415-419.
101. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002, 13:134-141.
102. Gainsford T., Willson T.A., Metcalf D., et al. Leptin can induce proliferation, differentiation, and functional activation of hematopoietic cells. Proc Natl Acad Sci USA 1996, 93:14564-14568.
103. Bouloume A., Marumo T., Lafontan M., Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999, 13:1231-1238.
104. Konstantinides S., Schafer K., Koschnick S., Loskutoff D.J. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001, 108:1533-1540.
105. Porreca E., Di Febbo C., Fusco L., Moretta V., Di Nisio M., Cuccurullo F. Soluble thrombomodulin and vascular adhesion molecule-1 are associated to leptin plasma levels in obese women. Atherosclerosis 2004, 172:175-180.
106. Patel L., Buckels A.C., Kinghorn I.J., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003, 300:472-476.
107. Axelsson J., Bergsten A., Qureshi A.R., et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006, 69:596-604.
108. Verma S., Li S.H., Wang C.H., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108:736-740.
109. Lehrke M., Reilly M.P., Millington S.C., Iqbal N., Rader D.J., Lazar M.A. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004, 1(e45):161-166.
110. Malyszko J., Malyszko J.S., Kozminski P., Pawlak K., Mysliwiec M. Elevated resistin is related to inflammation and residual renal function in hemodialyzed patients. Nephrology 2007, 12:246-253.
111. Yilmaz M.I., Saglam M., Carrero J.J., et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008, 23:959-965.
112. Kleinz M.J., Davenport A.P. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005, 107:198-211.
113. Boucher J., Masri B., Daviaud D., et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005, 146:1764-1771.
114. Japp A.G., Newby D.E. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008, 75:1882-1892.
115. Sheikh A.Y., Chun H.J., Glassford A.J., et al. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am J Physiol Heart Circ Physiol 2008, 294:H88-H98.
116. Malyszko J., Malyszko J.S., Kozminski P., Mysliwiec M. Apelin, a novel adipocytokine, and cardiac function in hemodialyzed patients: possible relations?. Am J Nephrol 2006, 26:121-126.
117. Fukuhara A., Matsuda M., Nishizawa M., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
118. Axelsson J., Witasp A., Carrero J.J., et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007, 49:237-244.
119. Malyszko J., Malyszko J.S., Mysliwiec M. Visfatin and endothelial function in dialyzed patients. Nephrology 2010, 15:190-196. (Carlton).
120. Seo J.A., Jang E.S., Kim B.G., et al. Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women. Diab Res Clin Pract 2008, 79:108-111.
121. Oki K., Yamane K., Kamei N., Nojima H., Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol 2007, 67:796-800. (Oxf).
122. Kato A., Odamaki M., Ishida J., Hishida A. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol 2009, 29:31-35.
123. Adams M.J., Irish A.B., Watts G.F., Oostryck R., Dogra G.K. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thromb Res 2008, 123:374-380.
124. Pawlak K., Pawlak D., Mysliwiec M. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. Thromb Res 2007, 120:797-803.
125. Ishiwata N., Takio K., Katayama M., et al. Alternatively spliced isoform of P-selectin is present in vivo as soluble molecule. J Biol Chem 1994, 38:23708-23715.
126. Zucker S., Mirza H., Conner C.E. Vascular endothelial growth factor induces tissue factor and matrix metaloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase-A activation and cell proliferation. Int J Cancer 1998, 75:780-785.
127. Blann A.D., Belgore F.M., Constans J., Conri C., Lip G.Y.H. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin and fenofibrate. Am J Cardiol 2001, 87:1160-1163.
128. Blann A.D., Lip G.Y.H. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinol 1998, 9:297-306.
129. Karmann K., Min W., Fanslow W.C., Pober J.S. Activation and homologous desensitization of human endothelial cells by CD 40 ligand, tumor necrosis factor, and interleukin 1. J Exp Med 1996, 184:173-182.
130. Slupsky J.R., Kalbas M., Willuweit A., Henn V., Kroczek R.A., Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD 40. Thromb Haemost 1998, 80:1008-1014.
131. Bardin N., Frances V., Lesaule G., Horschowski N., George F., Sampol J. Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun 1996, 218:210-216.
132. Bardin N., George F., Mutin M., et al. S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen. Tissue Antigens 1996, 548:531-539.
133. Bardin N., Moal V., Anfosso F., et al. Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost 2003, 90:915-920.
134. Meyer C., Heiss C., Drexhage C., et al. Hemodialysis-induced release of hemoglobin limits nitric oxide bioavailability and impairs vascular function. J Am Coll Cardiol 2010, 55:454-459.
135. Reiter C.D., Wang X., Tanus-Santos J.E., et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002, 8:1383-1389.
136. Rother R.P., Bell L., Hillmen P., Gladwin M.T. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005, 293:1653-1662.
137. Creager M.A., Lüscher T.F., Cosentino F., Beckman J.A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003, 108:1527-1532.
138. Navarro-Gonzalez J.F., Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008, 19:433-442.
139. Goldberg R.B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009, 94:3171-3182.
140. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Tesch G.H. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005, 16:1711-1722.
141. Sharma K., Ziyadeh F.N. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995, 44:1139-1146.
142. Hohenstein B., Hausknecht B., Boehmer K., Riess R., Brekken R.A., Hugo C.P. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 2006, 69:1654-1661.
143. de Vriese A.S., Tilton R.G., Elger M., Stephan C.C., Kriz W., Lameire N.H. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001, 12:993-1000.
144. Sung S.H., Ziyadeh F.N., Wang A., Pyagay P.E., Kanwar Y.S., Chen S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006, 17:3093-3104.
145. Makita Z., Radoff S., Rayfield E.J., et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991, 325:836-842.
146. Singh A.K., Mo W., Dunea G., Arruda J.A. Effect of glycated proteins on the matrix of glomerular epithelial cells. J Am Soc Nephrol 1998, 9:802-810.
147. Swaminathan S., Shah S.V. Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease. Curr Opin Nephrol Hypertens 2008, 17:143-148.
148. Menne J., Meier M., Park J.K., Haller H. Inhibition of protein kinase C in diabetic nephropathy-where do we stand?. Nephrol Dial Transplant 2009, 24:2021-2024.
149. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 2004, 34:785-796.
150. Kanwar Y.S., Wada J., Sun L., et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med 2008, 233:4-11. (Maywood).
151. Matsumoto K., Sera Y., Ueki Y., Inukai G., Niiro E., Miyake S. Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet Med 2002, 19:822-826.
152. Fasching P., Veitl M., Rohac M., et al. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996, 81:4313-4317.
153. Targher G., Bertolini L., Zoppini G., Zenari L., Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 2005, 22:999-1004.
154. Maier C., Clodi M., Neuhold S., et al. Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diab Care 2009, 32:1890-1895.
155. Chicheportiche Y., Bourdon P.R., Xu H., et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997, 272:32401-32410.
156. Winkles J.A. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-425.
157. Yilmaz M.I., Carrero J.J., Ortiz A., et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1716-1723.
158. Kralisch S., Ziegelmeier M., Bachmann A., et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008, 199:440-444.
159. Sonmez A., Yilmaz M.I., Saglam M., et al. The relationship between hemoglobin levels and endothelial functions in diabetes mellitus. Clin J Am Soc Nephrol 2010, 5:45-50.
160. Yilmaz M.I., Sonmez A., Saglam M., et al. Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease. Kidney Int 2009, 75:1316-1321.
161. Yilmaz M.I., Carrero J.J., Martín-Ventura J.L., et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 2010 Apr 29, Electronic publication ahead of print.
162. Yilmaz M.I., Sonmez A., Saglam M., et al. Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway. Nephrol Dial Transplant 2010, March 26, Electronic publication ahead of print.
163. Jensterle M., Sebestjen M., Janez A., et al. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol 2008, 159:399-406.
164. Ahmed A.K., Kamath N.S., El Kossi M., El Nahas M.A. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant October 10, 2009, Electronic publication ahead of print.